COMMUNIQUÉS West-GlobeNewswire

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
05/10/2026
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone [...]
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
05/10/2026
Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 05, [...]
Cannara Expands International Supply Agreement with Curaleaf
05/10/2026
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
05/10/2026
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in [...]
Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
05/10/2026
Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Gate [...]
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
05/10/2026
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options ZUG, Switzerland, Oct. 05, 2026 (GLOBE [...]
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
05/10/2026
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial [...]
Your Postal Code Shouldn’t Determine Your COPD Care. In Canada, It Still Does.
05/10/2026
Lung Health Foundation’s new Canadian COPD Performance Index finds significant shortfalls in COPD care across the country, driven by missing data, workforce shortages and no national strategy. Here’s where your region [...]
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
05/10/2026
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 ® (PCV20) and/or Capvaxive ® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 [...]
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer
05/10/2026
Appointment solidifies Cerevance’s leadership team as the company advances solengepras through Phase 3 development in Parkinson’s disease BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage [...]
OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting
05/10/2026
Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 At the September 23, 2026, data cutoff, CUSP06 achieved a 62% objective response [...]
Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
05/10/2026
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05/10/2026
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the [...]
Cannara étend son entente d’approvisionnement international avec Curaleaf
05/10/2026
MONTRÉAL, 05 oct. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), un producteur verticalement intégré de [...]
AID FOR AIDS and AID FOR LIFE to Celebrate 30 Years of Global Humanitarian Impact at My Hero Gala in New York
05/10/2026
“Dignity Across Borders” Gala Will Honor Edgar Ramírez, Nathalie Rayes, Maria Eugenia Maury and Mary Ann Torres, While Raising Critical Funds for HIV Treatment, Migrant Integration and Earthquake Recovery in Venezuela [...]
Zenflow Secures $52M Series D Financing and Announces Exclusive U.S. Distribution Partnership with Cook Medical
05/10/2026
Series D proceeds to support commercialization of the Zenflow Spring® System for Men with Enlarged Prostate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Zenflow, Inc., developer of the Zenflow Spring® [...]
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
05/10/2026
A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the [...]
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
05/10/2026
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth [...]

Pages